Barinthus Biotherapeutics PLC (BRNS) has a current Price-to-Book (P/B) ratio of 0.36. Compared to its 3-year average P/B ratio of 0.43, the current P/B ratio is approximately -16.83% higher. Relative to its 5-year average P/B ratio of 0.56, the current P/B ratio is about -36.65% higher. Barinthus Biotherapeutics PLC (BRNS) has a Forward Free Cash Flow (FCF) yield of approximately -103.18%. Compared to its 3-year average FCF yield of -75.11%, the current FCF yield is approximately 37.37% lower. Relative to its 5-year average FCF yield of -50.61%, the current FCF yield is about 103.88% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BRNS competitors is 3.48, providing a benchmark for relative valuation. Barinthus Biotherapeutics PLC Corp (BRNS.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BRNS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BRNS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BRNS currently overvalued or undervalued?

What is Barinthus Biotherapeutics PLC (BRNS) fair value?

BRNS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Barinthus Biotherapeutics PLC (BRNS) is between NaN to NaN according to relative valuation method.

How does BRNS's valuation metrics compare to the industry average?

The average P/S ratio for BRNS's competitors is 3.48, providing a benchmark for relative valuation. Barinthus Biotherapeutics PLC Corp (BRNS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for Barinthus Biotherapeutics PLC (BRNS) as of Mar 03 2026?

As of Mar 03 2026, Barinthus Biotherapeutics PLC (BRNS) has a P/B ratio of 0.36. This indicates that the market values BRNS at 0.36 times its book value.

What is the current FCF Yield for Barinthus Biotherapeutics PLC (BRNS) as of Mar 03 2026?

As of Mar 03 2026, Barinthus Biotherapeutics PLC (BRNS) has a FCF Yield of -103.18%. This means that for every dollar of Barinthus Biotherapeutics PLC's market capitalization, the company generates -103.18 cents in free cash flow.

What is the current Forward P/E ratio for Barinthus Biotherapeutics PLC (BRNS) as of Mar 03 2026?

As of Mar 03 2026, Barinthus Biotherapeutics PLC (BRNS) has a Forward P/E ratio of -0.50. This means the market is willing to pay $-0.50 for every dollar of Barinthus Biotherapeutics PLC's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Barinthus Biotherapeutics PLC (BRNS) as of Mar 03 2026?

As of Mar 03 2026, Barinthus Biotherapeutics PLC (BRNS) has a Forward P/S ratio of 0.00. This means the market is valuing BRNS at $0.00 for every dollar of expected revenue over the next 12 months.

BRNS Valuation